Search

everythinglearnresearchcommunity

for

Search:↓

Certain immune cells in the skin release a protein that stops hair growth by keeping hair stem cells inactive.

New insights into the causes and treatments for the autoimmune hair loss condition Alopecia areata have been made.

The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.

The study concluded that immune cells attacking hair follicles cause hair loss in alopecia, with genetics and environment also playing a role, and highlighted the potential of certain treatments.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.

Hepatitis B virus exposure may be linked to increased risk of alopecia areata.

The document concludes that understanding and treatments for alopecia areata have significantly advanced, now recognizing it as an autoimmune disorder.

Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.

Blocking certain immune signals can reduce skin damage from radiation therapy.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

Understanding hair growth involves complex factors, and more research is needed to improve treatments for hair loss conditions.

Understanding the cause of bitemporal hair loss is key to deciding the right treatment.

A condition with certain scalp changes may come before acne keloidalis nuchae and other similar hair loss disorders.

A woman's complete hair loss condition improved after recovering from COVID-19.

Hair follicles are key to treating vitiligo and alopecia areata, but challenges exist.

Pediatric alopecia areata is more immune-active than adult cases, suggesting age-specific treatments and potential use of JAK inhibitors.

Baricitinib successfully treated myasthenia gravis and alopecia in a patient.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.

Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.

Early genetic testing and JAK inhibitors can help treat systemic inflammation in SAVI patients.

The minoxidil gel could be a better treatment for hair loss than traditional forms.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Tofacitinib helped a woman with total-body hair loss grow her hair back.

A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.

Tofacitinib helped a woman regrow hair with no major side effects.

Some dermatologists in Saudi Arabia prescribe Tofacitinib for hair loss, but many don't due to its unavailability and safety concerns.

Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.

Baricitinib is a promising treatment for severe alopecia areata with minimal side effects.